Medico-social aspects of hepatocellular carcinoma

Niyaz Malayev, Samat Sagatovich Saparbayev, Saule Kubekova, Nurgul M. Kereyeva

2023

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.23950/jcmk/13257
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Oncological diseases are one of the leading health problems both in the world and in Kazakhstan, second only to cardiovascular diseases. Hepatocellular carcinoma occupies the 8th place in the structure of oncopathologies, has an unfavorable prognosis and an unfavorable course. According to the WHO, more than 1.3 million people die each year from hepatocellular carcinoma (HCC). The incidence rate of HCC in Kazakhstan is up to 5.5 cases per 100 thousand of the population, and the mortality rate remains high (about 1000 people annually). In 2017, 82.3% of HCC patients died before the end of the year. Five-year survival in HCC does not exceed 18%, and postoperative recurrence is about 50%.